A compound with no addiction potential and no organ damage
In a nation where more than 100 million people carry the quiet weight of chronic pain, and where the remedies on offer have too often traded one suffering for another, a New Orleans pharmaceutical company has received a rare federal mandate to pursue something better. The National Institutes of Health has awarded South Rampart Pharma $1.9 million through one of only 19 Fast-Track grants issued nationally in 2019, backing a non-opioid painkiller born from Louisiana university research that shows early promise of relieving pain without addiction, organ damage, or the cascading human costs that have defined this crisis. It is a small but deliberate step in the long arc of medicine's effort to heal without harm.
- Over 100 million Americans endure persistent pain while the two dominant treatments — opioids and common over-the-counter drugs — carry risks of addiction or organ failure that make long-term use a gamble with one's health.
- The opioid epidemic has made the search for a safer painkiller not merely a scientific ambition but a public health emergency, with the crisis costing the U.S. economy up to $635 billion every year in medical expenses and lost productivity.
- South Rampart Pharma, led by surgeon and CEO Dr. Hernan Bazan, is advancing a compound with a novel mechanism of action — one that preliminary evidence suggests can relieve pain without triggering addiction or damaging the liver and kidneys even with prolonged use.
- The NIH's rare Fast-Track STTR designation — the first awarded to a Louisiana company in a decade — signals institutional confidence that the underlying science is credible and the path toward human trials is worth accelerating.
- International experts, from Sweden's Karolinska Institutet to Germany's Center for Neurodegenerative Diseases, have underscored that a truly safe, non-addictive painkiller would carry global significance, particularly for elderly and chronically ill patients most harmed by current options.
South Rampart Pharma, a life science company rooted in New Orleans, has secured $1.9 million from the National Institute of Neurological Disorders and Stroke to develop a new class of painkillers — one designed to sidestep the twin dangers that have made existing options so fraught: the addictive pull of opioids and the organ damage caused by overuse of common alternatives. The grant came through the NIH's Fast-Track Small Business Technology Transfer program, a distinction awarded to only 19 projects across the entire country in 2019 and the first Louisiana has seen in a decade.
The compound traces its origins to LSU Health New Orleans, where it was discovered, patented, and eventually licensed to South Rampart Pharma. Under the leadership of Dr. Hernan Bazan, the company will use the funding to complete late-stage pre-clinical testing while maintaining a close research partnership with LSU's Neuroscience Center of Excellence. The work has already earned a publication in the European Journal of Medicinal Chemistry, lending it scientific standing ahead of any move toward human trials.
The stakes are difficult to overstate. Chronic pain touches more than 100 million Americans — lasting weeks, months, or years — and extracts between $560 billion and $635 billion annually from the economy in medical costs and lost productivity alone. The human toll extends further still, rippling through families and caregivers in ways that numbers cannot fully capture.
What South Rampart is chasing is a compound with a genuinely different mechanism of action — one that early evidence suggests could relieve pain without fostering dependence or harming vital organs over time. Dr. Nicolas Bazan, scientific co-founder of the company and director of the LSU Neuroscience Center, described the grant as affirmation of translational science: the disciplined work of carrying laboratory discoveries into clinical reality.
Voices from outside the company have amplified that optimism. Researchers at the Karolinska Institutet and the German Center for Neurodegenerative Diseases both noted that safer pain relief would matter most to elderly and chronically ill patients — those for whom current medications carry the greatest risk. The road ahead remains long, with regulatory hurdles and human trials still to come, but the NIH's decision to fast-track the project suggests the science beneath it is worth believing in.
South Rampart Pharma, a life science company based in New Orleans, has received $1.9 million from the National Institute of Neurological Disorders and Stroke to develop a new class of painkillers that carry none of the risks that have made opioids so dangerous or the organ damage that comes with overuse of common over-the-counter alternatives. The grant, awarded through the NIH's Fast-Track Small Business Technology Transfer program, represents a rare vote of confidence in early-stage drug development—only 19 such grants were awarded across the entire United States in 2019, and this is the first one Louisiana has received in a decade.
The drug itself emerged from research at LSU Health New Orleans, where it was discovered and patented before being licensed to South Rampart Pharma for development. The company, led by Dr. Hernan Bazan, a surgeon and CEO, will use the funding to push the medication through late-stage pre-clinical testing while continuing to work closely with LSU Health New Orleans' Neuroscience Center of Excellence to understand how pain actually works in the body. A paper describing the compound has already been published in the European Journal of Medicinal Chemistry, giving the work scientific credibility before it moves toward human trials.
The need for such a drug is urgent and vast. More than 100 million Americans live with pain that lasts for weeks, months, or years. That suffering carries a price tag that staggers the imagination: between $560 billion and $635 billion annually in direct medical costs and lost productivity. The burden falls not just on patients but on their families and the health care workers who care for them, all of whom must contend with both the physical and emotional toll of chronic pain.
Current options are bleak. Opioids work but are highly addictive and have fueled a public health catastrophe. Over-the-counter painkillers like ibuprofen and acetaminophen damage the liver and kidneys when used regularly. What South Rampart Pharma is pursuing is something genuinely different—a compound with a unique mechanism of action that preliminary evidence suggests could relieve pain without addiction potential and without harming vital organs, even with long-term use.
Dr. Nicolas Bazan, the scientific co-founder of South Rampart Pharma and director of the LSU Neuroscience Center, framed the grant as validation of a translational approach: taking discoveries made in the laboratory and moving them toward real clinical use. The Fast-Track designation matters because it signals that the NIH believes this project has genuine commercial potential and scientific merit worth accelerating.
Experts outside the company have taken notice. Dr. Robert Naismith, who has founded multiple life science companies and co-founded the Geisinger Commonwealth School of Medicine, called the discovery a potential major clinical advance. International researchers have also weighed in: Prof. Pierluigi Nicotera, founding director of the German Center for Neurodegenerative Diseases, emphasized that elderly patients with chronic illnesses are particularly vulnerable to the side effects of current pain medications and would benefit most from a safer option. Dr. Marianne Schultzberg, a neurobiology professor at the Karolinska Institutet in Sweden, noted that a non-addictive, effective, and safe painkiller would be of high importance globally.
The path from here is long. Pre-clinical development must be completed, regulatory approval must be sought, and human trials must prove the drug works and is safe. But the NIH's decision to fast-track this project suggests the underlying science is solid and the potential reward—a genuinely safer painkiller—is worth the investment.
Citações Notáveis
The discovery of a potentially safer new chemical entity for pain treatment has the potential to be a major clinical advance, with a unique mechanism of action recognized by the critical support of the NIH.— Dr. Robert Naismith, co-founder of Geisinger Commonwealth School of Medicine
This startup represents the clinical translational application of LSU Health New Orleans' discoveries, and this grant will help advance development of a non-narcotic drug with no abuse potential and no liver and kidney toxicity.— Dr. Nicolas Bazan, scientific co-founder of South Rampart Pharma
A Conversa do Hearth Outra perspectiva sobre a história
Why does a $1.9 million grant to a single company matter enough to report on?
Because it's rare. Only 19 of these fast-track grants were awarded in the entire country last year. Louisiana hadn't received one in a decade. The NIH doesn't hand these out lightly—it signals they believe this particular drug has real potential to reach patients.
But it's still pre-clinical. The drug isn't in people yet.
True. But that's exactly the point. This is the stage where most promising drugs die because there's no money to push them forward. The grant funds the work that has to happen before human trials can even begin. Without it, this compound might have stayed locked in a university lab.
What makes this drug different from what already exists?
The mechanism. It appears to relieve pain through a pathway that doesn't trigger addiction and doesn't damage the liver or kidneys. Current opioids work but destroy lives. Current over-the-counter drugs are safer but wreck your organs if you take them regularly. This is trying to split the difference.
Is there any guarantee it will work?
No. Pre-clinical work is promising, but plenty of drugs fail in human trials. What the grant does is give the company the resources to find out whether the promise is real.
Who benefits most if this succeeds?
The 100 million Americans living with chronic pain. But especially older people with multiple illnesses who can't tolerate the side effects of what's available now. They're the ones most trapped by the current choices.